Effects of quercetin and vitamin E on ovariectomy-induced oxidative stress in rat serum and tibia

Sina Vakili¹, Fatemeh Zal¹,², *, Zohreh Mostafavipour¹, Amir Savardashtaki³, Majid Jafari Khorchani¹ and Ashraf Hassanpour⁴

¹Biochemistry Department, Medical School, Shiraz University of Medical Sciences, Shiraz, Iran
²Traditional Medicine and Medical History Research Centre, Shiraz University of Medical Sciences, Shiraz, Iran
³Biotechnology Department, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran
⁴Anatomical Department, Medical School, Shiraz University of Medical Sciences, Shiraz, Iran

*Corresponding author: fatemehzal@yahoo.com

Received: November 15, 2019; Revised: December 15, 2019; Accepted: January 13, 2020; Published online: January 20, 2020

Abstract: Estrogen deficiency after menopause accelerates redox imbalance, leading to oxidative stress (OS) and other postmenopausal complications such as osteoporosis and cardiovascular disease. In the present study, the effects of quercetin (Q), vitamin E (vitE) and estradiol (E2) on the oxidative status in ovariectomized (OVX) rats were investigated. OVX animals were treated with Q (15 mg/kg/day), vitE (60 mg/kg/day), E2 (10 µg/kg/day) and Q (7.5 mg/kg/day)+vitE (30 mg/kg/day) for 10 weeks. OS markers were analyzed in the serum and tibia of rats. Data indicated that after ovariectomy, rats exhibited a reduction in serum and tibia antioxidants and elevation of oxidant markers. The activities of antioxidant enzymes (AOEs), glutathione peroxidase (GPx), catalase (CAT) and glutathione reductase were decreased and the glutathione (GSH) content was reduced, whereas the malondialdehyde (MDA) level was increased. Treatment with Q, vitE and E2 markedly reversed these changes and improved OS. In conclusion, prevention by antioxidant agents, including Q and vitE, could be a potential approach in the management of menopause-related complications.

Keywords: menopause; ovariectomy; osteoporosis; oxidative stress; quercetin; vitamin E

INTRODUCTION

Menopause is defined by the final menstrual period and generally occurs when women are between 45 and 55 years of age [1]. Menopause is associated with different short-term consequences such as mood changes, vasomotor symptoms, urogenital difficulties, joint pains and long-term consequences, including osteoporosis, cardiovascular diseases (CVDs), neurologic disorders, sexual difficulties and metabolic dysfunction [1,2]. The marked decrease in ovarian steroid secretion, mainly estradiol (E2), is responsible for these symptoms [2]. Estrogen deficiency has been reported to reduce antioxidant defenses and to increase the expression of some inflammatory cytokines [3]. Osteoporosis is one of the most common consequences of the menopause [2]. Bone homeostasis is maintained through a dynamic balance between bone-forming osteoblasts and bone-resorbing osteoclasts [4]. Oxidative stress (OS) can disrupt this balance, leading to the advent of osteoporosis [5]. The role of estrogens is clearly indicated in osteoporosis through their protective effects against OS and inflammation in bone [6,7]. Furthermore, the beneficial effects of estrogen, such as those on neurons, endothelial cells and other tissues, are considered to occur through improved defenses against OS [3,8].

Estrogen prescription as hormone replacement therapy (HRT) is the main choice to prevent the onset or to relieve postmenopausal symptoms [9]. However, long-term HRT is associated with several adverse effects, such as increased risk of breast cancer, stroke, venous thromboembolism, cholecystitis and endo-
maternal hyperplasia [10,11]. Moreover, the beneficial effects of HRT failed to prevent the development of cardiovascular complications according to the Heart and Estrogen/Progestin Replacement Study (HERS) and the Women’s Health Initiative (WHI) [12]. Accordingly, several studies have suggested alternative treatments to HRT with few or no reported side effects, based on the phytoestrogenic, antioxidant and antiinflammatory properties of natural compounds and vitamins [13,14].

Quercetin (3,5,7-trihydroxy-2-(3,4-dihydroxyphenyl)-4Hchromen-4-one) (Q) [5] is a dietary flavonol phytoestrogen found in tomato, onion, black chokeberry, caper and lettuce [15]. Q has several health benefits, including antioxidant [16], antiinflammatory [17], hepatoprotective, gastroprotective [1], anticancer and antibacterial [18], as well as the ability to attenuate some CVDs [15]. This indicates that the prescription of Q might become a potential alternative treatment for diseases induced by oxidative stress (OS) and inflammation, including menopausal consequences [15].

Vitamin E (vitE), mainly α-tocopherol, is a powerful antioxidant with a significant effect in protecting bone loss caused by OS [19,20]. There are several reports on vitE actions in neuroprotection and antiinflammation. Prevention of atherosclerosis and ovariectomy-induced memory deficits are another protective effects of vitE [21,22]. The main idea behind the researches on vitE and bone metabolism stems from the concept that OS can affect the bone formation activity of osteoblasts, which in turn can result in osteoporosis [23].

In light of the above, the OS footprint is seen in most menopausal consequences, including osteoporosis. Protecting against oxidative stress after menopause seems to be an important approach along with HRT. Thus, the current study was designed to evaluate the antioxidant effect of Q and vitE in serum and tibia of ovariectomized (OVX) rats, as a well-established animal model for postmenopausal pathophysiological changes [24], compared with synthetic steroidal estrogen as a reference HRT.

MATERIALS AND METHODS

Chemicals

Q, GSH, GR, oxidized glutathione (GSSG), nicotinamide adenine dinucleotide phosphate (NADPH), bovine serum albumin (BSA), 1,1,3,3-tetraethoxypropane (TEP), 5,5′-dithiobis-2-nitrobenzoic acid and tert-butyl hydroperoxide (tBuOOH) were purchased from the Sigma Chemical Company (St. Louis, Missouri, USA). Hydrogen peroxide (H₂O₂), trichloroacetic acid, potassium phosphate, ethylenediaminetetraacetic acid (EDTA), sodium azide and sodium chloride were obtained from Merck (Darmstadt, Germany). VitE (α-tocopherol), E₂ and other chemicals were obtained from standard commercial suppliers.

Animals

This study was approved by the ethics committee of the Shiraz University of Medical Sciences. A total of 64 three-month-old female Sprague-Dawley rats in regular estrous cycles were used in the study. The animals were maintained under a 12h/12h dark/light regimen at room temperature, with free access of water and rodent standard chow. The rats were randomly divided into eight different groups (8 rats in each group). All treatments were administered by gavage in a maximum volume of 1 mL during 10 weeks. All rats were randomly divided into 8 groups, as follows: Group 1: sham operated (SH); Group 2: ovariectomy (OVX); Group 3: ovariectomy + 3% ethanol as Q vehicle (OVX-ETH); Group 4: ovariectomy + rapeseed oil as vitE vehicle (OVX-Oil); Group 5: ovariectomy + 15 mg/kg/day Q (OVX-Q); Group 6: ovariectomy + 60 mg/kg/day vitE (OVX-vitE); Group 7: ovariectomy + 10 μg/kg/day E₂ (OVX-E₂); Group 8: ovariectomy + 7.5 mg/kg/day Q + 30 mg/kg/day vitE (OVX-Q-vitE). All treatments were initiated one week after ovariectomy. Dosage and duration of Q, E₂ and vitE administrations were based on previous works [25-27].

Ovariectomy procedure

Rats were anesthetized by intraperitoneal (i.p.) injection of ketamine (60 mg/kg) and xylazine (5 mg/kg). Bilateral ovariectomy was carried out by a dorsal approach as previously described [28]. Briefly, the dorsal
region of animals was shaved and cleaned with 70% ethanol. Under sterile conditions, a single 2-cm-long incision was made and both ovaries were removed. The gap was then sutured and tetracycline and lidocaine ointments were applied locally over the incision area.

Sample collection

After 10 weeks of treatment, blood samples were collected from the heart and the obtained serum was stored at -80°C for biochemical analysis; both tibias from each killed rat were dissected and cleaned of adherent tissues and stored at -80°C before analysis.

Tibia homogenate preparation

Frozen tibias were placed into liquid nitrogen and completely pulverized with a pestle. Powdered bone was homogenized in 4 mL of normal saline with a homogenizer for 30 s. The homogenate was centrifuged at 10000×g for 45 min at 4°C and the supernatant was used for biochemical analysis.

Serum 17β-estradiol measurement

The 17β-estradiol serum level was measured using a commercially-available ELISA kit according to the manufacturer’s instructions.

Determination of GPx activity

To determine GPx activity, the rate of NADPH oxidation was measured by spectrophotometry at 340 nm for 150 s in the presence of GSH, tBuOOH and GR [29]. Enzyme activity was expressed as U/L and U/g of protein for the serum and tibia, respectively.

Determination of GR activity

GR activity was determined by the method of Hafeman with minor modifications [30]. The tibia homogenate supernatant (or serum) was added to the mixture containing potassium phosphate buffer, EDTA, sodium azide, GSSG and BSA. The reaction was initiated by adding NADPH. GR activity was assayed by reduction of absorbance at 340 nm over a 3 min period and was expressed as U/L and U/g of protein for serum and tibia respectively.

Determination of CAT activity

The method of Aebi was used to measure CAT activity based on some modifications in previous studies [31]. Briefly, a mixture containing the homogenate supernatant, H2O2, potassium phosphate buffer and deionized water was prepared and the reaction was initiated by the addition of H2O2, and release of H2O2 by CAT was monitored by following the reduction in absorbance at 240 nm for 2 min. Enzyme activity was expressed as U/g of protein.

Estimation of the GSH content

The GSH content of serum and tibia homogenate supernatant was determined by the reaction of GSH with 5,5’-dithiobis-2-nitrobenzoic acid. The colored product of the reaction was measured by spectrophotometry at 412 nm [32]. The obtained tibia GSH content was normalized by total protein concentration estimated from each sample by the Bradford method. Data was expressed as nmol/mL and nmol/mg of protein for serum and tibia, respectively.

Estimation of MDA levels

MDA in the serum and tibia was measured as described [33] with some modifications. Briefly, the serum or tibia homogenate supernatant was mixed with 2 mL of thiobarbituric acid (TBA) reagent and then incubated at 100°C for 15 min. After centrifugation at 1500×g at 4°C for 5 min, the MDA level was spectrophotometrically measured at 532 nm using tetraethoxypropane (TEP) as standard and expressed as nmol/mg of protein and nmol/mL for tibia and serum, respectively. Tibia MDA values were normalized using total protein concentration, measured by Bradford’s method using BSA as standard. A SHIMADZU UV-1700 UV/visible spectrophotometer (Kyoto, Japan) was used for all colorimetric assays.

Statistical analysis

All data are expressed as the mean±standard error of mean (M±SEM). The Kolmogorov-Smirnov test was used to determine the normality of data. Differences between groups were analyzed using Kruskal-Wallis with post-hoc Mann-Whitney U test. The statistical
analyses were performed using SPSS software version 23.0 for Windows. A value of \( P < 0.05 \) was considered as statistically significant.

**RESULTS**

Changes in serum 17β-estradiol levels

Serum 17β-estradiol levels were significantly decreased in OVX rats compared to the SH group \(( p < 0.05 \)). Treatments did not make any significant change in 17β-estradiol levels of ovariectomized rats (Fig.1).

Effect of quercetin, vitE and estradiol on GPx activity

The serum GPx activity in the OVX rats was significantly reduced by 42% in comparison to the SH group \(( p < 0.05 \)). Daily administration of E2, vitE and Q to OVX rats for 10 weeks significantly increased the activity of GPx compared to the untreated OVX group \(( p < 0.05 \) for all three). Simultaneous administration of Q and vitE had a similar effect but with lower intensity \(( p < 0.05 \) \) (Fig. 2A). Tibia GPx activity was reduced by 47% when rats were ovariectomized \(( p < 0.05 \)) \( \). Tibia GPx activity was significantly increased in OVX-E2, OVX-vitE, OVX-Q and OVX-vitE-Q rats compared to the OVX group \(( p < 0.05 \) \( \) to the extent that they did not differ significantly from the SH group (Fig. 2B).

Effect of Q, vitE and E2 on GR activity

The serum GR activity in the OVX rats was significantly reduced by 47% in comparison to SH group \(( p < 0.05 \)). Treating the OVX rats with E2, vitE or Q significantly increased serum GR activity \(( p < 0.05 \) \). Although the co-administration of
Tibia CAT activity was reduced by 73% when rats were ovariectomized (p<0.001). CAT activity was increased significantly in OVX-E2, OVX-vitE and OVX-Q rats when compared to the OVX group (p<0.05). Co-administration of Q and vitE increased CAT activity in comparison with the OVX group but the difference was not significant (Fig. 4).

Effects of Q, vitE and E2 on the GSH content

The serum GSH content in OVX rats was significantly decreased by more than 81% when compared to the SH group (p<0.05). E2, vitE and Q treatments resulted in a significant increase in the level of GSH in the serum of OVX rats (p<0.001 for E2, p<0.05 for Q and vitE). The increase in the GSH content in the OVX-Q-vitE group was not significant when compared to the OVX group (p<0.05) (Fig. 5A). The tibia GSH content decreased by 47% in rats after ovariectomy (p<0.05). Tibia GSH was increased by 26%, 33%, 42% and 20% in OVX-E2, OVX-vitE, OVX-Q and OVX-vitE-Q groups, respectively, compared to the OVX group (p>0.05 for E2 and Q+vitE, p<0.05 for Q and vitE). There were no significant differences regarding the GSH content between SH, OVX-E2, OVX-vitE, OVX-Q and OVX-vitE-Q groups (Fig. 5B).

Effects of Q, vitE and E2 on MDA levels

The serum MDA level of OVX rats was significantly higher than the SH group (p<0.05). The MDA levels were decreased by 30%, 26% and 37% in E2, vitE and Q treated rats, respectively, when compared to the non-treated OVX group (p<0.05). Although co-administration of Q and vitE reduced the level of MDA, the difference was not significant compared to the OVX group (Fig. 6A). The level of tibia MDA increased by 19% in OVX rats when compared to the SH group (p>0.05). Compared to the OVX group, rats

Q and vitE increased the activity of both GR and GPx by 31% and 39%, respectively, these incremental effects were weaker than other treated groups (p<0.05) for both enzymes as compared to the OVX group (Figs. 3A). The activity of GR in tibia was reduced by 76% when rats were ovariectomized (p<0.05). Tibia GR activity was increased by 78%, 75% and 76% in E2, vitE and Q treated rats, respectively, as compared to the OVX group (p<0.05). Although the Q+vitE treatment increased GR activity by 71% in comparison with the OVX group, the difference was not significant (p=0.09) (Fig. 3B).
DISCUSSION

Menopause, a form of reproductive aging, is characterized by a complete failure of ovarian tissue to produce estrogen, which leads to an increase in OS, bone loss, CVDs, neurologic and sexual disorders [34]. Ovariectomy is the most common animal model for postmenopausal changes [21]. In the present study, we evaluated the effects of E2, vitE and Q on ovariectomy-induced OS in the serum and tibia of female rats. Our data demonstrated that ovariectomy induced an imbalance between ROS production and the antioxidant defense system, and the resulting OS was accompanied by a marked decrease in GPx, GR and CAT activities, GSH content and an increase in MDA level. These changes were improved by administration of either E2, vitE or Q in comparison with untreated OVX rats. Co-administration of Q and vitE had a weaker improving effect than when each compound was applied alone. Our findings demonstrated that Q and vitE markedly protected against ovariectomy-induced OS in female rats.

GPx and GR are the first line of defense of antioxidant enzymes against OS. We found that ovariectomy reduced GPx and GR activities in both serum and tibia of female rats. E2 treatment reversed these changes to the extent that they did not differ significantly from the SH group, suggesting that estrogen depletion after ovariectomy is likely the main reason for OS induction. Degradation of hydrogen peroxide is catalyzed by CAT enzyme. Tibia CAT activity was also decreased after ovariectomy and improved by E2 administration, emphasizing the role of estrogen on preventing OS. Serum CAT activity was not assayed because of sample volume limitation. It was previously suggested [3] that the increase in hydrogen peroxide together with the decrease in the superoxide dismutase (SOD), GPx and glutathione S transferase (GST) activities in ovariectomized rats is the main factor behind bone loss in experimental animals.

GSH is a cellular thiol-containing nonenzymatic antioxidant that plays an important role in the removal of free radicals [35]. In the current study, the tibia and serum GSH contents in the OVX rats were markedly depleted compared to the SH group and improved after E2 treatment. Other studies [1] indicate that ovariectomy induces OS and lipid peroxidation, as demonstrated by the increase in MDA level and decrease in GSH content. Since GR is responsible for GSSG reduction, the decrease in GSH after ovariectomy may be due to GR depletion.

MDA is a lipid peroxidation product that increases as a result of the oxidant/antioxidant imbalance in tissues [36-38]. We observed that ovariectomy could induce MDA production in the serum and tibia of female rats. The MDA level was decreased after E2 treatment, suggesting that estrogen deficiency and the resulting OS after ovariectomy may be the reason of MDA production. These changes were not significant as regards the tibia, indicating that MDA alterations start earlier in the serum compared to bone tissue. In agreement with current data, several studies showed that MDA levels in tissues increase after ovariectomy because of estrogen depletion [1,3,28,36]. Oxidized lipids can affect osteoclastic and osteoblastic bone cells [39]. As MDA reacts with amino groups, it can inhibit the synthesis of proteins and also deactivate certain enzymes [40]. For this reason, the reduction in tibia and serum antioxidant enzyme activities observed after OVX may be due to increased lipid per-
oxidation, as demonstrated in other studies [3,36]. OS induction has been suggested to result in bone loss [36,41], to contribute to CVDs [42], neurologic disorders [43,44] and other consequences of menopause or ovariectomy. Thus, we assumed that defense against OS could be a potential approach to improve menopause-derived complications.

Q, a potent antioxidant and phytoestrogen, is widely present in human diet. Thus, it is essential to understand the effects of Q on human health [15]. Compared to trolox, a water-soluble analog of vitE, Q could remarkably improve the endogenous antioxidant activity of 2,2’-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid (ABTS) [45]. Our results indicate that Q treatment after ovariectomy reduced the levels of MDA and increased the GSH content and antioxidant enzyme activities in serum and tibia compared to the OVX group. These ameliorating effects of Q on OS are comparable to the effects of E2 on rats for all measured OS markers in both the serum and the tibia. In agreement with the current study, Dong et al. [46] indicated that treatment with a high dose of Q significantly enhanced the activities of GPx and SOD although it significantly decreased the level of MDA. Coskun et al. [47] demonstrated that the protective effect of Q on β-cell is attributed to its antioxidant nature. Wei Liang et al. [48] found that Q has some beneficial effects on osteopenia induced by diabetes in rats and suggested that Q could be a potential therapeutic drug for diabetic osteopenia. Further studies indicated that Q is capable of reversing bone resorption, subsequently reducing loss of bone mass in rats [48]. Q also has phytoestrogenic properties as a result of structural similarities to estrogen and binding capabilities to estrogen receptors that stimulate calcium absorption [1]. This may explain the beneficial effects of Q on bone health in addition to its antioxidant properties. Because phytoestrogens have been suggested to be estrogen receptor modulators, they may be used in postmenopausal women to improve some health risks associated with estrogen deficiency [13]. Q has both phytoestrogenic and antioxidant properties and could be a potential therapeutic approach for relieving menopausal complications. However, there are inconsistent literature data with regard to the effects of Q on estrogen receptors [1], and more research is needed to prove its beneficial effects as an alternative to HRT.

VitE defends cells against damage from oxygen free radicals and lipid peroxides [49]. We evaluated the antioxidant ability of Q along with vitE as a widely-known antioxidant. Our results showed that there was no significant difference between the antioxidant effects of Q and vitE in both serum and tibia. Similar to Q, vitE reduced lipid peroxidation and increased the GSH content and antioxidant enzyme activities in both serum and tibia to the extent that they did not differ significantly from the SH group. This is compatible with previous findings [50] where it was revealed that vitE supplementation protected several tissues against radical damage. It was observed [50] that there is a significant protective effect of vitE in combination with Se on GPx, GR, SOD and CAT of the heart, kidney, liver and testis of sodium azide-treated mice. VitE prevents peroxidation of membrane lipids and is converted into a tocopheroxyl radical by scavenging lipid peroxyl radicals [51]. VitE has been reported to protect from bone loss and damage caused by OS [20,52]. However, no significant association between vitE and bone structural changes or negative results has been reported in human epidemiological studies [53,54], suggesting that amelioration of OS alone may not guarantee bone health.

Many biological processes like oxidative homeostasis regulation are influenced by vitE and Q. We assumed that they synergize the protective effects of each other. Unexpectedly, our results revealed that co-administration of Q and vitE produced lower beneficial effects on the oxidative status of serum and tibia. Although the OVX-Q-vitE group had an improved oxidative status compared to the OVX non-treated group, the differences were not significant as regards all measured OS markers, except tibia GPx activity. This can be explained by the fact that stability of Q could be influenced by temperature [55], pH [56], the presence of metal ions [57] and concentrations of other antioxidants [15]. It was suggested [15] that the chemical stability and bioavailability of Q can be affected by the presence of other antioxidants. Furthermore, Q can readily form noncovalent associations with vitE in membranes [58]. These may influence the stability and absorption of Q and vitE in the gastrointestinal tract and reduce their concentrations in the plasma. The combination of Q, vitE and vitamin C in cadmium OS-induced rats showed a synergic antioxidant pattern compared to rats treated only with
Q [59], indicating a contrary finding to that reported in the present study. This discrepancy may be due to the fact that the authors evaluated hepatic oxidative markers and the co-administration of three Q, vitE and vitamin C antioxidants, whereas we assessed only Q and vitE in combination in serum and bone tissue.

It is concluded from the present study that menopause/ovariectomy-induced OS can be ameliorated by the administration of Q and vitE and this can relieve menopause/ovariectomy-related dysfunctions. With quercetin's documented safety profile in humans, clinical trials into the potential benefit of Q in treating menopause-derived complications in humans should be performed.

**Funding:** This paper is a part of the PhD thesis of Sina Vakili and was supported by Grant Number 18208 from the Vice-Chancellor for Research Affairs of Shiraz University of Medical Sciences.

**Author contributions:** Sina Vakili assisted with the design of the study, carried out all the experiments and participated in manuscript preparation. Fatemeh Zal carried out the design and coordinated the study, participated in most of the experiments and data analysis and manuscript correction. Zohreh Mostafavipour and Amir Savardashtaki assisted with the design of the study and provided assistance for enzyme assay experiments. Majid Jafari Khorchani and Ashraf Hassanpour provided assistance for the experimental design and animal surgery. All authors have read and approved the content of the manuscript.

**Conflict of interest disclosure:** The authors declare that there are no conflicts of interest.

**REFERENCES**


50. Hamza RZ, Al-Harbi MS, El-Shenawy NS. Ameliorative effect of vitamin E and selenium against oxidative stress induced by...


